- Home
- CRGX vs PVBC Comparison
CRGX vs PVBC Comparison
Compare CRGX & PVBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- PVBC
- Stock Information
- Founded
- CRGX 2021
- PVBC 1913
- Country
- CRGX United States
- PVBC United States
- Employees
- CRGX N/A
- PVBC N/A
- Industry
- CRGX
- PVBC Major Banks
- Sector
- CRGX
- PVBC Finance
- Exchange
- CRGX Nasdaq
- PVBC Nasdaq
- Market Cap
- CRGX 190.0M
- PVBC 202.6M
- IPO Year
- CRGX 2023
- PVBC 2015
- Fundamental
- Price
- CRGX $4.20
- PVBC $12.53
- Analyst Decision
- CRGX Hold
- PVBC Hold
- Analyst Count
- CRGX 7
- PVBC 1
- Target Price
- CRGX $4.67
- PVBC $12.50
- AVG Volume (30 Days)
- CRGX 591.0K
- PVBC 405.3K
- Earning Date
- CRGX 08-11-2025
- PVBC 07-28-2025
- Dividend Yield
- CRGX N/A
- PVBC N/A
- EPS Growth
- CRGX N/A
- PVBC N/A
- EPS
- CRGX N/A
- PVBC 0.26
- Revenue
- CRGX N/A
- PVBC $50,244,000.00
- Revenue This Year
- CRGX $57.81
- PVBC $9.73
- Revenue Next Year
- CRGX N/A
- PVBC $4.87
- P/E Ratio
- CRGX N/A
- PVBC $48.07
- Revenue Growth
- CRGX N/A
- PVBC N/A
- 52 Week Low
- CRGX $3.00
- PVBC $9.67
- 52 Week High
- CRGX $25.45
- PVBC $12.96
- Technical
- Relative Strength Index (RSI)
- CRGX 44.13
- PVBC 80.47
- Support Level
- CRGX $4.07
- PVBC $12.04
- Resistance Level
- CRGX $4.31
- PVBC $12.17
- Average True Range (ATR)
- CRGX 0.17
- PVBC 0.16
- MACD
- CRGX -0.03
- PVBC 0.06
- Stochastic Oscillator
- CRGX 18.62
- PVBC 91.58
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About PVBC Provident Bancorp Inc. (MD)
Provident Bancorp Inc provides a range of banking products and services to small and medium-sized commercial customers. It attracts deposits from the general public and uses those funds to originate loans, commercial real estate, construction and land, and commercial business loans, and to invest in securities. The company lending activities include providing commercial real estate loans, multi-family residential real estate loans, commercial business loans, construction and land development loans, one-to four-family residential loans, home equity loans & lines of credit, and consumer loans.